XML 48 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segments of Business and Geographic Areas
 12 Months Ended
Dec. 30, 2018
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas
Segments of Business and Geographic Areas

 
 
Sales to Customers
 
% Change
(Dollars in Millions)
 
2018
 
2017
 
2016
 
’18 vs. ’17
 
’17 vs. ’16
 
 
 
 
 
 
 
 
 
 
 
CONSUMER
 
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
 
 
     U.S.
 
$
422

 
449

 
488

 
(6.0
)%
 
(8.0
)
     International
 
1,436

 
1,467

 
1,513

 
(2.1
)
 
(3.0
)
     Worldwide
 
1,858

 
1,916

 
2,001

 
(3.0
)
 
(4.2
)
Beauty
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,403

 
2,335

 
2,135

 
2.9

 
9.4

     International
 
1,979

 
1,865

 
1,762

 
6.1

 
5.8

     Worldwide
 
4,382

 
4,200

 
3,897

 
4.3

 
7.8

Oral Care
 
 
 
 
 
 
 
 
 
 
     U.S.
 
637

 
616

 
648

 
3.4

 
(4.9
)
     International
 
918

 
915

 
920

 
0.3

 
(0.5
)
     Worldwide
 
1,555

 
1,531

 
1,568

 
1.6

 
(2.4
)
OTC
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,850

 
1,716

 
1,675

 
7.8

 
2.4

     International
 
2,484

 
2,410

 
2,302

 
3.1

 
4.7

     Worldwide
 
4,334

 
4,126

 
3,977

 
5.0

 
3.7

Women's Health
 
 
 
 
 
 
 
 
 
 
     U.S.
 
13

 
12

 
19

 
8.3

 
(36.8
)
     International
 
1,036

 
1,038

 
1,048

 
(0.2
)
 
(1.0
)
     Worldwide
 
1,049

 
1,050

 
1,067

 
(0.1
)
 
(1.6
)
Wound Care/Other
 
 
 
 
 
 
 
 
 
 
     U.S.
 
436

 
437

 
455

 
(0.2
)
 
(4.0
)
     International
 
239

 
342

 
342

 
(30.1
)
 
0.0

     Worldwide
 
675

 
779

 
797

 
(13.4
)
 
(2.3
)
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
 
     U.S.
 
5,761

 
5,565

 
5,420

 
3.5

 
2.7

     International
 
8,092

 
8,037

 
7,887

 
0.7

 
1.9

     Worldwide
 
13,853

 
13,602

 
13,307

 
1.8

 
2.2

 
 
 
 
 
 
 
 
 
 
 
PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
Immunology
 
 
 
 
 
 
 
 
 
 
     U.S.
 
9,073

 
8,871

 
8,846

 
2.3

 
0.3

     International
 
4,047

 
3,373

 
3,122

 
20.0

 
8.0

     Worldwide
 
13,120

 
12,244

 
11,968

 
7.2

 
2.3

     REMICADE®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3,664

 
4,525

 
4,842

 
(19.0
)
 
(6.5
)
     U.S. Exports
 
436

 
563

 
782

 
(22.6
)
 
(28.0
)
     International
 
1,226

 
1,227

 
1,342

 
(0.1
)
 
(8.6
)
     Worldwide
 
5,326

 
6,315

 
6,966

 
(15.7
)
 
(9.3
)
 
 
 
 
 
 
 
 
 
 
 
     SIMPONI / SIMPONI ARIA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,051

 
954

 
959

 
10.2

 
(0.5
)
     International
 
1,033

 
879

 
786

 
17.5

 
11.8

     Worldwide
 
2,084

 
1,833

 
1,745

 
13.7

 
5.0

     STELARA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3,469

 
2,767

 
2,263

 
25.4

 
22.3

     International
 
1,687

 
1,244

 
969

 
35.6

 
28.4

     Worldwide
 
5,156

 
4,011

 
3,232

 
28.5

 
24.1

     TREMFAYA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
453

 
62

 
—

 
*
 
*
     International
 
91

 
1

 
—

 
*
 
*
     Worldwide
 
544

 
63

 
—

 
*
 
*
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—

 
—
     International
 
10

 
22

 
25

 
(54.5
)
 
(12.0
)
     Worldwide
 
10

 
22

 
25

 
(54.5
)
 
(12.0
)
 
 
 
 
 
 
 
 
 
 
 
Infectious Diseases
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,378

 
1,358

 
1,461

 
1.5

 
(7.0
)
     International
 
1,926

 
1,796

 
1,747

 
7.2

 
2.8

     Worldwide
 
3,304

 
3,154

 
3,208

 
4.8

 
(1.7
)
     EDURANT® / rilpivirine
 
 
 
 
 
 
 
 
 
 
     U.S.
 
58

 
58

 
52

 
0.0

 
11.5

     International
 
758

 
656

 
521

 
15.5

 
25.9

     Worldwide
 
816

 
714

 
573

 
14.3

 
24.6

     PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,169

 
1,109

 
1,143

 
5.4

 
(3.0
)
     International
 
786

 
712

 
708

 
10.4

 
0.6

     Worldwide
 
1,955

 
1,821

 
1,851

 
7.4

 
(1.6
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
 
     U.S.
 
151

 
191

 
266

 
(20.9
)
 
(28.2
)
     International
 
382

 
428

 
518

 
(10.7
)
 
(17.4
)
     Worldwide
 
533

 
619

 
784

 
(13.9
)
 
(21.0
)
 
 
 
 
 
 
 
 
 
 
 
Neuroscience
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,574

 
2,630

 
2,628

 
(2.1
)
 
0.1

     International
 
3,503

 
3,356

 
3,457

 
4.4

 
(2.9
)
     Worldwide
 
6,077

 
5,986

 
6,085

 
1.5

 
(1.6
)
     CONCERTA® / Methylphenidate
 
 
 
 
 
 
 
 
 
 
     U.S.
 
229

 
384

 
468

 
(40.4
)
 
(17.9
)
     International
 
434

 
407

 
395

 
6.6

 
3.0

     Worldwide
 
663

 
791

 
863

 
(16.2
)
 
(8.3
)
     INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,791

 
1,590

 
1,343

 
12.6

 
18.4

     International
 
1,137

 
979

 
871

 
16.1

 
12.4

     Worldwide
 
2,928

 
2,569

 
2,214

 
14.0

 
16.0

     RISPERDAL CONSTA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
315

 
360

 
381

 
(12.5
)
 
(5.5
)
     International
 
422

 
445

 
512

 
(5.2
)
 
(13.1
)
     Worldwide
 
737

 
805

 
893

 
(8.4
)
 
(9.9
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
 
     U.S.
 
239

 
296

 
436

 
(19.3
)
 
(32.1
)
     International
 
1,510

 
1,525

 
1,679

 
(1.0
)
 
(9.2
)
     Worldwide
 
1,749

 
1,821

 
2,115

 
(4.0
)
 
(13.9
)
 
 
 
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
 
 
 
     U.S.
 
4,331

 
3,098

 
2,335

 
39.8

 
32.7

     International
 
5,513

 
4,160

 
3,472

 
32.5

 
19.8

     Worldwide
 
9,844

 
7,258

 
5,807

 
35.6

 
25.0

     DARZALEX®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,203

 
884

 
471

 
36.1

 
87.7

     International
 
822

 
358

 
101

 
*
 
*
     Worldwide
 
2,025

 
1,242

 
572

 
63.0

 
*
     IMBRUVICA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,129

 
841

 
613

 
34.2

 
37.2

     International
 
1,486

 
1,052

 
638

 
41.3

 
64.9

     Worldwide
 
2,615

 
1,893

 
1,251

 
38.1

 
51.3

     VELCADE®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—

 
—
     International
 
1,116

 
1,114

 
1,224

 
0.2

 
(9.0
)
     Worldwide
 
1,116

 
1,114

 
1,224

 
0.2

 
(9.0
)
     ZYTIGA® /abiraterone acetate
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,771

 
1,228

 
1,089

 
44.2

 
12.8

     International
 
1,727

 
1,277

 
1,171

 
35.2

 
9.1

     Worldwide
 
3,498

 
2,505

 
2,260

 
39.6

 
10.8

     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
 
     U.S.
 
228

 
145

 
162

 
57.2

 
(10.5
)
     International
 
362

 
359

 
338

 
0.8

 
6.2

     Worldwide
 
590

 
504

 
500

 
17.1

 
0.8

 
 
 
 
 
 
 
 
 
 
 
Pulmonary Hypertension
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,651

 
773

 
—

 
*
 
*
     International
 
922

 
554

 
—

 
66.4

 
*
     Worldwide
 
2,573

 
1,327

 
—

 
93.9

 
*
     OPSUMIT®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
700

 
320

 
—

 
*
 
*
     International
 
515

 
253

 
—

 
*
 
*
     Worldwide
 
1,215

 
573

 
—

 
*
 
*
     TRACLEER®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
268

 
161

 
—

 
66.5

 
*
     International
 
278

 
242

 
—

 
14.9

 
*
     Worldwide
 
546

 
403

 
—

 
35.5

 
*
 
 
 
 
 
 
 
 
 
 
 
     UPTRAVI®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
598

 
238

 
—

 
*
 
*
     International
 
65

 
25

 
—

 
*
 
*
     Worldwide
 
663

 
263

 
—

 
*
 
*
     OTHER 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
85

 
54

 
—

 
57.4

 
*
     International
 
64

 
34

 
—

 
88.2

 
*
     Worldwide
 
149

 
88

 
—

 
69.3

 
*
Cardiovascular / Metabolism / Other
 
 
 
 
 
 
 
 
 
 
     U.S.
 
4,279

 
4,744

 
4,855

 
(9.8
)
 
(2.3
)
     International
 
1,537

 
1,543

 
1,541

 
(0.4
)
 
0.1

     Worldwide
 
5,816

 
6,287

 
6,396

 
(7.5
)
 
(1.7
)
     XARELTO®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,477

 
2,500

 
2,288

 
(0.9
)
 
9.3

     International
 
—

 
—

 
—

 
—

 
—

     Worldwide
 
2,477

 
2,500

 
2,288

 
(0.9
)
 
9.3

     INVOKANA® / INVOKAMET®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
711

 
944

 
1,273

 
(24.7
)
 
(25.8
)
     International
 
170

 
167

 
134

 
1.8

 
24.6

     Worldwide
 
881

 
1,111

 
1,407

 
(20.7
)
 
(21.0
)
     PROCRIT® / EPREX®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
674

 
675

 
767

 
(0.1
)
 
(12.0
)
     International
 
314

 
297

 
338

 
5.7

 
(12.1
)
     Worldwide
 
988

 
972

 
1,105

 
1.6

 
(12.0
)
     OTHER
 
 
 
 
 
 
 
 
 
 
     U.S.
 
417

 
625

 
527

 
(33.3
)
 
18.6

     International
 
1,053

 
1,079

 
1,069

 
(2.4
)
 
0.9

     Worldwide
 
1,470

 
1,704

 
1,596

 
(13.7
)
 
6.8

TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
     U.S.
 
23,286

 
21,474

 
20,125

 
8.4

 
6.7

     International
 
17,448

 
14,782

 
13,339

 
18.0

 
10.8

     Worldwide
 
40,734

 
36,256

 
33,464

 
12.4

 
8.3

 
 
 
 
 
 
 
 
 
 
 
MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
 
 
     U.S.
 
371

 
612

 
739

 
(39.4
)
 
(17.2
)
     International
 
638

 
1,003

 
1,050

 
(36.4
)
 
(4.5
)
     Worldwide
 
1,009

 
1,615

 
1,789

 
(37.5
)
 
(9.7
)
Diagnostics
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—

 
—

     International
 
—

 
1

 
66

 
*
 
*
     Worldwide
 
—

 
1

 
66

 
*
 
*
Interventional Solutions
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,283

 
1,148

 
1,031

 
11.8

 
11.3

     International
 
1,363

 
1,148

 
1,024

 
18.7

 
12.1

     Worldwide
 
2,646

 
2,296

 
2,055

 
15.2

 
11.7

Orthopaedics
 
 
 
 
 
 
 
 
 
 
     U.S.
 
5,281

 
5,404

 
5,438

 
(2.3
)
 
(0.6
)
     International
 
3,604

 
3,654

 
3,690

 
(1.4
)
 
(1.0
)
     Worldwide
 
8,885

 
9,058

 
9,128

 
(1.9
)
 
(0.8
)
     HIPS
 
 
 
 
 
 
 
 
 
 
     U.S.
 
841

 
827

 
798

 
1.7

 
3.6

     International
 
577

 
567

 
563

 
1.8

 
0.7

     Worldwide
 
1,418

 
1,394

 
1,361

 
1.7

 
2.4

     KNEES
 
 
 
 
 
 
 
 
 
 
     U.S.
 
911

 
948

 
943

 
(3.9
)
 
0.5

     International
 
591

 
575

 
581

 
2.8

 
(1.0
)
     Worldwide
 
1,502

 
1,523

 
1,524

 
(1.4
)
 
(0.1
)
     TRAUMA
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,599

 
1,576

 
1,545

 
1.5

 
2.0

     International
 
1,100

 
1,040

 
1,024

 
5.8

 
1.6

     Worldwide
 
2,699

 
2,616

 
2,569

 
3.2

 
1.8

     SPINE & OTHER
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,930

 
2,053

 
2,152

 
(6.0
)
 
(4.6
)
     International
 
1,336

 
1,472

 
1,522

 
(9.2
)
 
(3.3
)
     Worldwide
 
3,266

 
3,525

 
3,674

 
(7.3
)
 
(4.1
)
Surgery
 
 
 
 
 
 
 
 
 
 
     U.S.
 
4,125

 
4,085

 
4,026

 
1.0

 
1.5

     International
 
5,776

 
5,474

 
5,270

 
5.5

 
3.9

     Worldwide
 
9,901

 
9,559

 
9,296

 
3.6

 
2.8

     ADVANCED
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,657

 
1,620

 
1,524

 
2.3

 
6.3

     International
 
2,345

 
2,136

 
1,993

 
9.8

 
7.2

     Worldwide
 
4,002

 
3,756

 
3,517

 
6.5

 
6.8

     GENERAL
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,751

 
1,728

 
1,669

 
1.3

 
3.5

     International
 
2,806

 
2,735

 
2,693

 
2.6

 
1.6

     Worldwide
 
4,557

 
4,463

 
4,362

 
2.1

 
2.3

     SPECIALTY
 
 
 
 
 
 
 
 
 
 
     U.S.
 
717

 
737

 
833

 
(2.7
)
 
(11.5
)
     International
 
625

 
603

 
584

 
3.6

 
3.3

     Worldwide
 
1,342

 
1,340

 
1,417

 
0.1

 
(5.4
)
Vision
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,777

 
1,575

 
1,032

 
12.8

 
52.6

     International
 
2,776

 
2,488

 
1,753

 
11.6

 
41.9

     Worldwide
 
4,553

 
4,063

 
2,785

 
12.1

 
45.9

     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,237

 
1,122

 
1,032

 
10.2

 
8.7

     International
 
2,065

 
1,914

 
1,753

 
7.9

 
9.2

     Worldwide
 
3,302

 
3,036

 
2,785

 
8.8

 
9.0

 
 
 
 
 
 
 
 
 
 
 
     SURGICAL
 
 
 
 
 
 
 
 
 
 
     U.S.
 
540

 
453

 
—

 
19.2

 
*
     International
 
711

 
574

 
—

 
23.9

 
*
     Worldwide
 
1,251

 
1,027

 
—

 
21.8

 
*
 
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
     U.S.
 
12,837

 
12,824

 
12,266

 
0.1

 
4.5

     International
 
14,157

 
13,768

 
12,853

 
2.8

 
7.1

     Worldwide
 
26,994

 
26,592

 
25,119

 
1.5

 
5.9

 
 
 
 
 
 
 
 
 
 
 
WORLDWIDE
 
 
 
 
 
 
 
 
 
 
     U.S.
 
41,884

 
39,863

 
37,811

 
5.1

 
5.4

     International
 
39,697

 
36,587

 
34,079

 
8.5

 
7.4

     Worldwide
 
$
81,581

 
76,450

 
71,890

 
6.7
 %
 
6.3

*Percentage greater than 100% or not meaningful

 
 
Income Before Tax
 
Identifiable Assets
(Dollars in Millions)
 
2018 (3)
 
2017 (4)
 
2016 (5)
 
2018
 
2017
Consumer
 
$
2,320

 
2,524

 
2,441

 
$
25,877

 
25,030

Pharmaceutical
 
12,568

 
11,083

 
12,827

 
56,636

 
59,450

Medical Devices
 
4,397

 
5,392

 
5,578

 
46,254

 
45,413

Total
 
19,285

 
18,999

 
20,846

 
128,767

 
129,893

Less: Expense not allocated to segments (1)
 
1,286

 
1,326

 
1,043

 
 
 
 
General corporate (2)
 
 
 
 
 
 
 
24,187

 
27,410

Worldwide total
 
$
17,999

 
17,673

 
19,803

 
$
152,954

 
157,303


 
 
Additions to Property,
Plant & Equipment
 
Depreciation and
Amortization
(Dollars in Millions)
 
2018
 
2017
 
2016
 
2018
 
2017
 
2016
Consumer
 
$
438

 
485

 
486

 
$
688

 
674

 
608

Pharmaceutical
 
1,012

 
936

 
927

 
3,802

 
2,416

 
886

Medical Devices
 
1,843

 
1,566

 
1,472

 
2,103

 
2,216

 
1,928

Segments total
 
3,293

 
2,987

 
2,885

 
6,593

 
5,306

 
3,422

General corporate
 
377

 
292

 
341

 
336

 
336

 
332

Worldwide total
 
$
3,670

 
3,279

 
3,226

 
$
6,929

 
5,642

 
3,754


 
 
Sales to Customers
 
Long-Lived Assets (6)
(Dollars in Millions)
 
2018
 
2017
 
2016
 
2018
 
2017
United States
 
$
41,884

 
39,863

 
37,811

 
$
37,117

 
38,556

Europe
 
18,753

 
17,126

 
15,770

 
51,433

 
56,677

Western Hemisphere excluding U.S. 
 
6,113

 
6,041

 
5,734

 
2,752

 
2,990

Asia-Pacific, Africa
 
14,831

 
13,420

 
12,575

 
2,733

 
2,773

Segments total
 
81,581

 
76,450

 
71,890

 
94,035

 
100,996

General corporate
 
 
 
 
 
 
 
1,064

 
1,143

Other non long-lived assets
 
 
 
 
 
 
 
57,855

 
55,164

Worldwide total
 
$
81,581

 
76,450

 
71,890

 
$
152,954

 
157,303

­
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In 2017, the Company had two wholesalers distributing products for all three segments that represented approximately 14.0% and 10.0% of the total consolidated revenues. In 2016, the Company had two wholesalers distributing products for all three segments that represented approximately 13.5% and 10.7% of the total consolidated revenues.

(1) 
Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.
(2) 
General corporate includes cash, cash equivalents and marketable securities.
(3) 
The Consumer segment includes a gain of $0.3 billion from the divestiture of NIZORAL® and litigation expense of $0.3 billion. The Pharmaceutical segment includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion, Actelion acquisition related costs of $0.2 billion, unrealized loss on securities of $0.2 billion and a gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products. The Medical Devices segment includes net litigation expense of $1.7 billion, a restructuring related charge of $0.6 billion, AMO acquisition related costs of $0.1 billion and a gain of $0.5 billion from the divestiture of the LifeScan business in the fiscal fourth quarter.
(4) 
The Pharmaceutical segment includes $0.8 billion for Actelion acquisition related costs, an in-process research and development expense of $0.4 billion and litigation expense of $0.1 billion. The Medical Devices segment includes litigation expense of $1.1 billion, a restructuring related charge of $0.8 billion, an asset impairment of $0.2 billion primarily related to the insulin pump business and $0.1 billion for AMO acquisition related costs. The Medical Devices segment includes a gain of $0.7 billion from the divestiture of Codman Neurosurgery. The Consumer segment includes a gain of $0.5 billion from the divestiture of COMPEED®.
(5) 
Includes net litigation expense of $0.8 billion and a restructuring related charge of $0.7 billion in the Medical Devices segment. The Pharmaceutical segment includes a positive adjustment of $0.5 billion to previous reserve estimates and gains from the divestitures of the controlled substance raw material and active pharmaceutical ingredient (API) business and certain anesthetic products in Europe.
(6) 
Long-lived assets include property, plant and equipment, net for 2018, and 2017 of $17,035 and $17,005, respectively, and intangible assets and goodwill, net for 2018 and 2017 of $78,064 and $85,134, respectively.